The London-based respiratory drug developer is reporting that interim results from the first part of its Phase II trial — showing that its dry powder inhaler formulation of ensifentrine helped patients improve lung function — look promising enough to go ahead with part 2.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,